Adamas Investor Day

September 18, 2017

Commercial plans and market opportunity for their recently approved drug (GOCOVRI™) for the treatment

of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, and an overview of the pipeline products.

 

Date:  September 18, 2017

Time:  8:00AM - 11:00AM

 

Guest Speaker:

Rajesh Pahwa, MD, Laverne & Joyce Rider
Professor of Neurology at the Kansas Medical Center and Director,
Parkinson's Disease Center of Excellence at the University of Kansas Health System

 

For more information or to RSVP, please contact Marcy Nanus (mnanus@troutgroup.com)

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Adamas Pharmaceuticals, Inc. ADMS $647 MM MCap
Fo­cused on de­vel­op­ing drugs for chron­ic neu­ro­log­i­cal di­s­or­ders by uti­l­iz­ing time-de­pen­dent bi­ol­o­gy to match ther­a­peu­tic drug pro­files with dis­ease pat­terns to drive a more sig­ni­f­i­cant durable ef­fect. [more in­for­ma­tion]